drugset
drugset / Trial / NCT03808857

A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

NCT03808857 ↗

Phase 2 Unknown 80 enrolled Genor Biopharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is a multi-center, prospective, open-label, single-arm phase II clinical study to evaluate the efficacy, safety and immunogenicity of GB226 in treatment of recurrent or metastatic cervical cancer patients with PD-L1 positive who failed in platinum-based chemotherapy.

Timeline

Start
2019-05-23
Primary completion
2021-12
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject APL-501 Monoclonal antibody 3 mg/kg —

Indications

cervical cancer